Structural basis for topoisomerase VI inhibition by the anti-Hsp90 drug radicicol

Kevin D. Corbett, James M. Berger

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Members of the GHL ATPase superfamily, including type II topoisomerases, Hsp90-class chaperones, and MutL, all share a common GHKL-type ATP-binding fold and act as nucleotide-controlled 'molecular clamps'. These enzymes' ATP-binding sites have proven to be rich drug targets, and certain inhibitors of type II topoisomerases and Hsp90 bind to this region and competitively inhibit these enzymes. Recently, it was found that radicicol, a drug known to block Hsp90 function, also inhibits the archaeal type IIB topoisomerase topo VI. Here, we use X-ray crystallography to show that despite low sequence identity (∼10-12%) between topo VI and Hsp90, radicicol binds to the ATPase sites of these two enzymes in an equivalent manner. We further demonstrate that radicicol inhibits both the dimerization of the topo VI ATPase domains and ATP hydrolysis, two critical steps in the enzyme's strand passage reaction. This work contributes to a growing set of structures detailing the interactions between GHL-family proteins and various drugs, and reveals radicicol as a versatile scaffold for targeting distantly related GHL enzymes.

Original languageEnglish (US)
Pages (from-to)4269-4277
Number of pages9
JournalNucleic acids research
Issue number15
StatePublished - Sep 2006
Externally publishedYes

ASJC Scopus subject areas

  • Genetics


Dive into the research topics of 'Structural basis for topoisomerase VI inhibition by the anti-Hsp90 drug radicicol'. Together they form a unique fingerprint.

Cite this